DIVISLABNSEDivi's Laboratories Limited· PharmaceuticalsHighNeutral
Announced Sat, 17 May · 13:44 IST

Divi's Laboratories Limited has informed the Exchange about change in Management.

Cfo ResignedKmp ResignedManagement Changes View source PDF

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Divi's Labs reported strong FY25 numbers with consolidated total income of ₹9,712 crores versus ₹8,184 crores last year. Standalone profit after tax for FY25 jumped to ₹2,209 crores from ₹1,576 crores, a growth of about 40%, with full-year EPS of ₹83.20. Q4 FY25 was also robust with standalone revenue of ₹2,536 crores and PAT of ₹667 crores. The Board recommended a final dividend of ₹30 per share (1500%) for FY25, with record date July 25, 2025 and AGM on August 11, 2025. The Unit III greenfield project at Kakinada, Andhra Pradesh commenced commercial operations during the quarter. Statutory auditors Price Waterhouse issued an unmodified opinion on the results.

Likely market impact

Strong earnings growth, healthy dividend yield and a new plant coming online are positives for shareholders. The orderly CFO transition, with a long-tenured internal successor taking over from the retiring CFO, signals continuity in financial leadership and is unlikely to cause any disruption.